Advanced search
Publication Cover
Clinical Lipidology Volume 5, 2010 - Issue 4
Submit an article Journal homepage
30
Views
2
CrossRef citations to date
0
Altmetric
Reviews

Attainment of combined optimal lipid values: a paradigm shift in the management of dyslipidemia

Mark J CzirakyCorrespondence[email protected]
&
Tyan ThomasPhiladelphia College of Pharmacy, University of the Sciences in Philadelphia, PA, USA
Pages 527-541 | Published online: 18 Jan 2017

  • Superko HR, King S: Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 117, 560–568 (2008).
  • ▪ Review of the data supporting achieving optimal levels of all lipid values.
  • Sharrett AR, Ballantyne CM, Coady SA et al.: Coronary heart disease prediction from lipoprotein cholesterol levels, triglyerides, lipoprotein(a), apoliproteins A-I and B, and HDL density subfractions: the atherosclerosis risk in communities (ARIC) study. Circulation 104, 1108–1113 (2001).
  • Koro CE, Bowlin SJ, Stump TE et al.: The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events. Am. Heart J. 141, E1–E6 (2006).
  • Jacobson TA, Miller M, Schaefer EJ: Hypertriglyceridemia and cardiovascular risk reduction. Clin. Ther. 2007, 763–777 (2007).
  • Brown BG, Zhao X, Chait, A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345, 1583–1592 (2001).
  • Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ: Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr. Med. Res. Opin. 3, 553–563 (2007).
  • Quimbo RA, Simko RJ, Cziraky MJ et al.: Attainment of combined optimal lipid values and the impact of lipid medication on cardiovascular outcomes and costs in a commercially insured population in the US. J. Med. Economics 11, 449–470 (2008).
  • Taylor AJ, Sullenberger LE, Lee HJ et al.: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebocontrolled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110, 3512–3517 (2004).
  • Taylor AJ, Lee HJ, Sullenerger LE: The effect of 24 months of combination statin and extended-release niacin on carotid intima–media thickness: ARBITER 3. Curr. Med. Res. Opin. 22, 2243–2250 (2006).
  • Nissen SE, Nicholls SJ, Sipahi I. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. J. Am. Med. Assoc. 295, 1556–1565 (2006).
  • Kastelein JJP, Akdim F, Stroes ESG et al.: Simvastatin with or without ezetimibe in familial hypecholesterolemia. N. Engl. J. Med. 358, 1431–1443 (2008).
  • Brown BG, Taylor AJ: Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N. Engl. J. Med. 358, 1504–1507 (2008).
  • Sarawate CA, Cziraky MJ, Stanek EJ et al.: Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed? Clin. Ther. 29, 1–14 (2007).
  • Mosca L, Merz NB, Blumenthal RS et al.: Opportunity for intervention to achieve american heart association guidelines for optimal lipid levels in high-risk women in a managed care setting. Circulation 111, 488–493 (2005).
  • Charland SL, Cziraky MJ, Quimbo R et al.: Achieving optimal lipid values in patterns with dyslipidemia is associated with reduced risk of cardiovascular events. J. Clin. Lipidol. 2, 343–353 (2008).
  • Pederson TR, Kjekshus J, Berg K et al.: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 344, 1383–1389 (1994).
  • Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo controlled trial. Lancet 360, 7–22 (2002).
  • Sever PS, Dahlof B, Poulter NR et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 361, 1149–1158 (2003).
  • Sacks FM, Pfeffer MA, Moye LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001–1009 (1996).
  • Shepard J, Cobbe SM, Ford I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333, 1301–1307 (1995).
  • Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on LDL cholesterol, ischemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326, 1423–1427 (2003).
  • Callhoun HM, Betteridge DJ, Durrington PN et al.: Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebocontrolled tiral. Lancet 364, 685–696 (2004).
  • Taylor AJ, Villines TC, Stanek EJ et al.: Extended-release niacin or ezetimibe and carotid intima–media thickness. N. Engl. J. Med. 361, E1–E10 (2009).
  • ▪▪ Demonstrates that in patients with optimal LDL-C levels the addition of niacin to attain total lipid panel control yields greater risk reductions than adding ezetimibe to further lower LDL-C levels.
  • Grover SA, Kaouache M, Joseph L et al.: Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Arch. Intern. Med. 169, 1775–1708 (2009).
  • The ACCORD study group: Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563–1574 (2010).
  • Briel M, Ferreira-Gonzalez I, You JJ et al.: Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338, B92 (2009).
  • Pasternak RC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C: ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Circulation 106, 1024–1028 (2002).
  • Coons SJ, Sheahan SL, Martin SS et al.: Predictors of medication noncompliance in a sample of older adults. Clin. Ther. 16, 110–117 (1994).
  • Alderman CP: Patient-oriented strategies for the prevention of drug interactions. Drug Safety 2, 103–109 (2000).
  • Sharma M, Ansari MT, Abou-Setta A et al.: Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann. Int. Med. 151, 622–630 (2009).
  • Barter PJ, Caulfield M, Eriksson M et al.: Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007).
  • Ansell BJ, Watson KE, Fogelman AM: High-density lipoprotein function: recent advances. J. Am. Coll. Cardiol. 46, 1792–1798 (2005).
  • Sorrentino SA, Besler C, Rohrer L et al.: Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with Type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 121, 110–122 (2010).
  • van der Steeg WA, Holme I, Bokholdt MJ et al.: High-density cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk. J. Am. Coll. Card. 51, 634–642 (2008).
  • Luc G, Bard JM, Ferrieres J et al.: Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I-/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arteriosler. Thromb. Vasc. Biol. 22, 1155–1161 (2002).
  • Lamon-Fava S, Diffenderfer MR, Barrett A et al.: Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler. Thromb. Vasc. Biol. 28, 1672–1678 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.